Population and background
ADAURA enrolled resected non-small cell lung cancer patients meeting stage criteria and carrying specified EGFR mutations.
What the evidence shows
ADAURA randomised 682 resected, EGFR-mutated stage IB–IIIA patients. In the 2023 overall survival analysis, five-year overall survival in the full study population was 88% with osimertinib and 78% with placebo. Stage, mutation and post-operative conditions must match.
Conclusions that cannot be drawn
These results come from patients meeting post-operative stage and EGFR mutation criteria; they do not apply to all lung cancer patients. Treatment in China also requires checking the hospital plan, medicine supply, budget and follow-up after returning home.
Questions to ask your doctor
Do my EGFR mutation and post-operative stage meet the discussion criteria? Do I need other adjuvant treatment, how long will the proposed medicine continue, and how will reassessment and medicine supply be coordinated between countries?